Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Adalimumab, phototherapy improve QoL in psoriasis patients

20 Sep 2019

Both adalimumab and phototherapy increase overall and skin-related quality of life (QoL) in psoriasis patients, although phototherapy appears to be better, a recent study has shown.

Researchers randomly assigned 97 psoriasis patients to receive phototherapy (n=33; mean age, 42.0±14.0 years; 69.7 percent male), adalimumab (n=33; mean age, 44.2±14.0 years; 72.7 percent male) or placebo (n=31; mean age, 44.3±14.5 years; 60.5 percent male). QoL outcomes were measured every 4 weeks using the Dermatology Life Quality Index (DLQI) and the three-level version of the five-dimension EuroQol (EQ-5D-3L) tool.

At baseline, the mean DLQI scores in the placebo, adalimumab and phototherapy arms were 12.13, 13.67 and 12.79, respectively. Corresponding scores in the EQ-5D index were 0.80, 0.78 and 0.72. After 12 weeks, statistically significant improvements in skin-related health-related QoL were reported in all groups.

However, both the adalimumab (difference, –3.80, 95 percent CI, –7.64 to 0.04) and phototherapy (difference, –4.80, –8.67 to –0.93) interventions produced significantly greater change relative to placebo.

Similarly, both adalimumab- (odds ratio [OR], 2.88, 1.02–8.17) and phototherapy-treated patients (OR, 8.83, 2.47–31.57) were significantly more likely to reach clinically meaningful improvement, as assessed by DLQI, than their placebo-treated counterparts.

Phototherapy was also more likely than adalimumab to elicit changes that achieved the minimal clinically important difference, although falling short of statistical significance (OR, 3.07, 0.85–11.13).

Both active treatments similarly outperformed placebo in terms of generic health-related QoL, inducing significantly greater improvements in EQ-5D-3L scores by week 12.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.